The apoptotic and antiangiogenic properties of withaferin-A were shown to be significantly reduced in vimentin-deficient cells [308], and withaferin-A treatments have been shown to be beneficial in vivo for patients with breast cancer [309], cervical cancer [310], and pancreatic cancer [311]. The gene discussed is VIM; the disease is breast cancer.